The effect of sclerostin on the proliferation, migration, and invasion abilities of two different breast cancer cell lines (MCF-7 and MDA-MB-231) was investigated by inhibiting sclerostin with an inhibitory antibody at different doses (1 and 4 μg/mL) and time periods (1, 2 and 3 days). Here, SOST is linked to breast cancer.